Skip to main content

Quest Diagnostics Value Stock - Dividend - Research Selection

Quest diagnostics

ISIN: US74834L1008 , WKN: 904533

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company\'s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-19
Quest Diagnostics Incorporated (NYSE: DGX), a leading national provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a presentation and Q&A session at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 4:30 p.m. Pacific Time.

Quest Diagnostics Incorporated's (NYSE:DGX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

2025-12-19
Quest Diagnostics (NYSE:DGX) has had a rough month with its share price down 5.3%. But if you pay close attention, you...

Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors

2025-12-18
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors

Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors

2025-12-16
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors

Quest Diagnostics Stock: Is DGX Outperforming the Healthcare Sector?

2025-12-15
Quest Diagnostics has outperformed the broader healthcare sector over the past year. Moreover, Wall Street analysts remain moderately optimistic about its prospects.

1 S&P 500 Stock to Target This Week and 2 We Brush Off

2025-12-12
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Quest Diagnostics Incorporated (DGX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

2025-12-02
Quest Diagnostics Incorporated (DGX) Citi Annual Global Healthcare Conference 2025 December 2, 2025 3:15 PM ESTCompany ParticipantsSam Samad - Executive VP...

Did Oracle's (ORCL) Debt-Fueled AI Expansion and New Board Member Just Shift Its Investment Narrative?

2025-12-02
In recent weeks, Oracle announced it unanimously elected former Quest Diagnostics CEO Stephen Rusckowski to its board, while Orca Security revealed its Cloud Native Application Protection Platform is now available in Oracle Cloud Marketplace for deployment on Oracle Cloud Infrastructure. This period also saw market and analyst focus shift toward Oracle's substantial increase in debt to fund AI data center expansion, prompting debate over its financial risk and reliance on large-scale OpenAI...

Quest Diagnostics Inc. stock underperforms Monday when compared to competitors

2025-12-01
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors

Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the United States

2025-12-01
MENLO PARK, Calif., December 01, 2025--Octave Bioscience, a commercial-stage precision care company pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases such as Parkinson’s disease, today announced a strategic collaboration with Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, to make the OctaveⓇ Multiple Sclerosis Disease Activity (MSDA) Test accessible through Quest’s nationwide specimen-collection network.